Table 2. Prevalence of Survival Without Major Comorbidities in Adulthood by Gestational Age at Birth and Birth Year, Sweden.
| Gestational Age at Birth | Total Births, No. | Survival | Survival and AYA HOPE Score = 0 | Survival and CCI Score = 0 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Age 18 y, % | End of Follow-up, % | Age 18 y, % | End of Follow-upa | Age 18 y, % | End of Follow-upb | ||||
| % | PR (95% CI)c | % | PR (95% CI)c | ||||||
| 1973-1997 | |||||||||
| All births, 1973-1997 (attained ages 18-43 y; median, 29.8 y) | 2 566 699 | 99.1 | 98.5 | 85.5 | 62.1 | 84.6 | 81.1 | ||
| Preterm (<37 wk) | 149 065 | 94.2 | 93.5 | 76.6 | 54.6 | 0.86 (0.85-0.86) | 76.9 | 73.1 | 0.89 (0.89-0.89) |
| Extremely (22-27 wk) | 5391 | 51.3 | 50.8 | 31.4 | 22.3 | 0.35 (0.33-0.36) | 36.3 | 32.5 | 0.39 (0.38-0.41) |
| Very (28-33 wk) | 33 025 | 89.5 | 88.8 | 68.4 | 48.5 | 0.76 (0.75-0.77) | 70.9 | 66.4 | 0.81 (0.80-0.81) |
| Late (34-36 wk) | 110 649 | 97.7 | 97.0 | 81.3 | 58.0 | 0.91 (0.91-0.92) | 80.7 | 77.1 | 0.94 (0.94-0.94) |
| Early term (37-38 wk) | 447 249 | 99.1 | 98.5 | 84.0 | 61.2 | 0.97 (0.96-0.97) | 83.8 | 80.4 | 0.98 (0.98-0.98) |
| Full-term (39-41 wk) | 1 742 809 | 99.4 | 98.9 | 86.2 | 63.0 | 1 [Reference] | 85.3 | 81.8 | 1 [Reference] |
| Postterm (≥42 wk) | 227 576 | 99.3 | 98.6 | 88.1 | 62.2 | 1.00 (0.99-1.00) | 85.5 | 81.5 | 1.00 (1.00-1.00) |
| Per additional wkd | 1.02 (1.02-1.02) | 1.02 (1.02-1.02) | |||||||
| 1973-1979 | |||||||||
| Born 1973-1979 (attained ages 36-43 y; median, 39.7 y) | 699 473 | 98.8 | 97.7 | 94.9 | 59.9 | 85.9 | 80.0 | ||
| Preterm (<37 wk) | 35 636 | 91.1 | 89.7 | 85.8 | 51.7 | 0.84 (0.83-0.85) | 77.2 | 70.9 | 0.87 (0.87-0.88) |
| Extremely (22-27 wk) | 1155 | 30.0 | 29.3 | 26.6 | 15.3 | 0.25 (0.21-0.28) | 24.9 | 21.4 | 0.26 (0.23-0.29) |
| Very (28-33 wk) | 7869 | 81.3 | 79.9 | 74.5 | 43.1 | 0.69 (0.68-0.71) | 67.7 | 61.2 | 0.75 (0.74-0.77) |
| Late (34-36 wk) | 26 612 | 96.6 | 95.2 | 91.7 | 55.8 | 0.91 (0.90-0.92) | 82.3 | 75.9 | 0.94 (0.93-0.94) |
| Early term (37-38 wk) | 98 895 | 98.8 | 97.6 | 94.6 | 59.3 | 0.96 (0.96-0.97) | 85.4 | 79.6 | 0.98 (0.98-0.98) |
| Full-term (39-41 wk) | 475 210 | 99.3 | 98.3 | 95.6 | 60.7 | 1 [Reference] | 86.6 | 80.8 | 1 [Reference] |
| Postterm (≥42 wk) | 89 732 | 99.2 | 98.1 | 95.4 | 59.9 | 1.00 (1.00-1.01) | 86.3 | 80.4 | 1.00 (1.00-1.00) |
| Per additional wkd | 1.02 (1.02-1.02) | 1.02 (1.02-1.02) | |||||||
| 1980-1989 | |||||||||
| Born 1980-1989 (attained ages 26-35 y; median, 30.7 y) | 989 229 | 99.1 | 98.5 | 89.6 | 62.4 | 86.0 | 82.2 | ||
| Preterm (<37 wk) | 60 203 | 94.7 | 93.9 | 82.1 | 55.6 | 0.87 (0.87-0.88) | 79.4 | 75.2 | 0.91 (0.90-0.91) |
| Extremely (22-27 wk) | 1957 | 50.9 | 50.2 | 35.6 | 22.8 | 0.36 (0.33-0.39) | 38.3 | 33.9 | 0.41 (0.38-0.43) |
| Very (28-33 wk) | 12 760 | 90.2 | 89.4 | 73.9 | 49.6 | 0.78 (0.76-0.79) | 73.7 | 68.6 | 0.83 (0.82-0.83) |
| Late (34-36 wk) | 45 486 | 97.9 | 97.1 | 86.4 | 58.8 | 0.92 (0.91-0.93) | 82.7 | 78.8 | 0.95 (0.94-0.95) |
| Early term (37-38 wk) | 186 892 | 99.2 | 98.5 | 88.8 | 61.5 | 0.97 (0.96-0.97) | 85.4 | 81.6 | 0.98 (0.98-0.99) |
| Full-term (39-41 wk) | 665 583 | 99.5 | 98.8 | 90.4 | 63.2 | 1 [Reference] | 86.7 | 82.9 | 1 [Reference] |
| Postterm (≥42 wk) | 76 551 | 99.3 | 98.6 | 90.7 | 62.9 | 0.99 (0.99-1.00) | 86.7 | 82.8 | 1.00 (1.00-1.00) |
| Per additional wkd | 1.02 (1.02-1.02) | 1.02 (1.01-1.02) | |||||||
| 1990-1997 | |||||||||
| Born 1990-1997 (attained ages 18-25 y; median, 22.5 y) | 877 997 | 99.3 | 99.1 | 73.1 | 63.6 | 81.8 | 80.6 | ||
| Preterm (<37 wk) | 53 226 | 95.7 | 95.6 | 64.2 | 55.4 | 0.85 (0.85-0.86) | 74.0 | 72.3 | 0.89 (0.88-0.89) |
| Extremely (22-27 wk) | 2279 | 62.5 | 62.3 | 30.2 | 25.4 | 0.39 (0.36-0.41) | 40.4 | 37.0 | 0.45 (0.43-0.47) |
| Very (28-33 wk) | 12 396 | 94.0 | 93.9 | 58.8 | 50.8 | 0.78 (0.76-0.79) | 69.9 | 67.4 | 0.82 (0.81-0.83) |
| Late (34-36 wk) | 38 551 | 98.3 | 98.1 | 68.0 | 58.7 | 0.90 (0.89-0.91) | 77.3 | 76.0 | 0.93 (0.92-0.94) |
| Early term (37-38 wk) | 161 462 | 99.3 | 99.2 | 71.9 | 62.1 | 0.96 (0.96-0.96) | 80.8 | 79.6 | 0.98 (0.97-0.98) |
| Full-term (39-41 wk) | 602 016 | 99.6 | 99.4 | 74.2 | 64.6 | 1 [Reference] | 82.7 | 81.5 | 1 [Reference] |
| Postterm (≥42 wk) | 61 293 | 99.5 | 99.3 | 74.1 | 64.6 | 1.00 (0.99-1.00) | 82.9 | 81.6 | 1.00 (1.00-1.01) |
| Per additional wkd | 1.02 (1.02-1.02) | 1.02 (1.02-1.02) | |||||||
Abbreviations: AYA HOPE, Adolescent and Young Adult Health Outcomes and Patient Experience; CCI, Charlson Comorbidity Index; PR, prevalence ratio.
a
Survival without any comorbidities in the AYA HOPE Comorbidity Index through 2015.
b
Survival without any comorbidities in the CCI through 2015.
c
Adjusted for child characteristics (birth year, sex, fetal growth, multiple birth, birth order) and maternal characteristics (age, education, smoking, preeclampsia, other hypertensive disorders, diabetes).
d
Per additional 1 week of gestation.